On January 5, 2022 Scorpion Therapeutics, Inc. ("Scorpion"), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, reported that it has been selected by BioSpace to join its NextGen Bio "Class of 2022 (Press release, Scorpion Therapeutics, JAN 5, 2022, View Source;utm_medium=rss&utm_campaign=scorpion-therapeutics-receives-biospace-nextgen-bio-class-of-2022-recognition [SID1234598307])." The recognition from BioSpace, a life sciences industry news outlet and career hub, highlights top up-and-coming biopharmaceutical companies to watch in the new year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to be a part of BioSpace’s NextGen Bio ‘Class of 2022’ and to join an esteemed list of companies being recognized for their potential to advance the biotech industry," said Axel Hoos, M.D., Ph.D., CEO of Scorpion. "This recognition for Scorpion reflects the team’s efforts to extend the frontiers of oncology research and patient care through our Precision Oncology 2.0 strategy."

For the past eight years, BioSpace NextGen Bio has honored the most innovative new biopharmaceutical companies from across the United States. Scorpion is one of 30 companies in the "Class of 2022" that was recognized based on a number of factors, including funding, collaborations, pipeline, growth potential and innovation.

On January 5, 2022 Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, reported that the Company will participate in three investor conferences during the month of January (Press release, Portage Biotech, JAN 5, 2022, View Source [SID1234598306]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of the Company’s participation, CEO Dr. Ian Walters will join other thought leaders in the oncology space two panel discussions on next-generation immuno-oncology therapies and the future of immuno-oncology at the LifeSci Partners 11th Annual Corporate Access Event and the H.C. Wainwright BioConnect Conference, respectively, and will also join a fireside chat discussion at the B. Riley Securities’ 2022 Oncology Conference.

Registration and other details for each event are as follows:

11th Annual LifeSci Partners Corporate Access Event
Date: January 5-7, 2022
Format: 1-on-1 investor meetings
Panel Discussion:
Next Gen Immune-Oncology Panel
January 7, 2022 at 7:30am ET
Registration – View Source

H.C. Wainwright BioConnect Conference
Date: January 10-13, 2022
Format: 1-on-1 investor meetings; on demand pre-recorded presentation available through conference portal
Panel Discussion:
New Directions in Immuno-Oncology

B. Riley Securities’ Oncology Investor Conference
Date: January 27-28, 2022
Format: Fireside chat January 28, 2022

On January 5, 2022 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, reported that the company is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET (Press release, Intellia Therapeutics, JAN 5, 2022, View Source [SID1234598305]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of Intellia’s presentation can be accessed under the Events and Presentations page of the Investors & Media section on the company’s website at www.intelliatx.com. A replay of the audio webcast will be available on Intellia’s website for at least two weeks following the presentation.

On January 5, 2022 Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, reported that senior leadership plans to present at the following conferences in January (Press release, Genocea Biosciences, JAN 5, 2022, View Source [SID1234598304]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conferences:

Event: Longwood Healthcare Leaders Winter Webconference – Details
Topic 1: Innovation in Cell Therapy
Format: Panel
Date: Thursday, January 6, 2022
Time: 1:30 PM ET
Topic 2: Making a Big Impact With Limited Resources
Format:
Date:
Time: Panel
Thursday, January 6, 2022
5:10 PM ET

Event:

LifeSci Partners 11th Annual Corporate Access Event – Details
Topic 1: Innovative Approaches to Cell Therapy for Oncology
Format: Panel
Date: Friday, January 7, 2022
Time: 8:30 AM ET
Topic 2: Cancer Vaccines: Promises, Promises … Has Their Day Come?
Format:
Date:
Time: Panel
Friday, January 7, 2022
2:00 PM ET

Event: H.C. Wainwright BIOCONNECT Virtual Conference – Details
Topic: Corporate Update
Format: On demand presentation
Date: Monday, January 10, 2022
Time: 7:00 AM ET

Event: Advanced Therapies Week – Details
Topic: Add It Up: 3 Things to Consider for Capacity Expansion
Format: Panel
Date: Wednesday, January 26, 2022
Time: 5:00 PM ET

On January 5, 2022 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported a strategic restructuring (Press release, FierceBiotech, JAN 5, 2022, View Source [SID1234598303]). The company will prioritize its late-stage product opportunities, poziotinib and ROLONTIS (eflapegrastim), and will deprioritize development activities of its early-stage clinical development and research programs. The company has made these decisions following a detailed review of its operations, portfolio and growth opportunities, and will focus its resources accordingly.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The decision to restructure the organization is necessary to focus on our advanced clinical programs that will drive our future growth. I would like to express my appreciation to our colleagues who are affected by this decision and are leaving Spectrum. We are grateful for their dedication and their contributions to advancing our mission," said Tom Riga, President and Chief Executive Officer, Spectrum Pharmaceuticals. "The changes we are implementing are expected to result in a reduction in operating expenses and the extension of the company’s cash runway into 2023."

Spectrum intends to implement the following strategic restructuring initiatives to reduce its expenses and extend its existing cash runway:

Spectrum is prioritizing the development activities for its late-stage assets, poziotinib and ROLONTIS, and will deprioritize work on its early-stage pipeline, FIT Program (IGN 002) and IL-12.
The company restructuring will result in a workforce reduction of approximately 30%.
Operating cash burn is expected to be reduced by 20-25%, which should extend the cash runway into 2023.
The physical footprint of selected facilities will be significantly reduced in 2022.